- Home
- RSLS
as 02-04-2025 4:00pm EST
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN CLEMENTE |
| Market Cap: | 3.2M | IPO Year: | 2007 |
| Target Price: | N/A | AVG Volume (30 days): | 43.6K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -17.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.23 - $29.00 | Next Earning Date: | 03-31-2025 |
| Revenue: | $8,183,000 | Revenue Growth: | -16.55% |
| Revenue Growth (this year): | 17.47% | Revenue Growth (next year): | 20.00% |
Latest ReShape Lifesciences Inc. News
RSLS Breaking Stock News: Dive into RSLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
GlobeNewswire
23 days ago
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
GlobeNewswire
3 months ago
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
GlobeNewswire
3 months ago
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
GlobeNewswire
3 months ago
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology
TipRanks
4 months ago
Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested
GlobeNewswire
5 months ago
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
Compare RSLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RSLS ReShape Lifesciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.